These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20235611)

  • 1. Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.
    Harikumar KG; Akgün E; Portoghese PS; Miller LJ
    J Med Chem; 2010 Apr; 53(7):2836-42. PubMed ID: 20235611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.
    Zheng Y; Akgün E; Harikumar KG; Hopson J; Powers MD; Lunzer MM; Miller LJ; Portoghese PS
    J Med Chem; 2009 Jan; 52(2):247-58. PubMed ID: 19113864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats.
    Quesada A; Micevych P
    Brain Res; 2006 Feb; 1073-1074():316-20. PubMed ID: 16472782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visualization of G protein-coupled receptor trafficking with the aid of the green fluorescent protein. Endocytosis and recycling of cholecystokinin receptor type A.
    Tarasova NI; Stauber RH; Choi JK; Hudson EA; Czerwinski G; Miller JL; Pavlakis GN; Michejda CJ; Wank SA
    J Biol Chem; 1997 Jun; 272(23):14817-24. PubMed ID: 9169450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.
    Le Naour M; Akgün E; Yekkirala A; Lunzer MM; Powers MD; Kalyuzhny AE; Portoghese PS
    J Med Chem; 2013 Jul; 56(13):5505-13. PubMed ID: 23734559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.
    Cawston EE; Harikumar KG; Miller LJ
    Am J Physiol Cell Physiol; 2012 Feb; 302(3):C615-27. PubMed ID: 22049215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual pathways of internalization of the cholecystokinin receptor.
    Roettger BF; Rentsch RU; Pinon D; Holicky E; Hadac E; Larkin JM; Miller LJ
    J Cell Biol; 1995 Mar; 128(6):1029-41. PubMed ID: 7896869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.
    Cussac D; Rauly-Lestienne I; Heusler P; Finana F; Cathala C; Bernois S; De Vries L
    Cell Signal; 2012 Aug; 24(8):1648-57. PubMed ID: 22560877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation.
    Wu SV; Harikumar KG; Burgess RJ; Reeve JR; Miller LJ
    Am J Physiol Gastrointest Liver Physiol; 2008 Sep; 295(3):G641-7. PubMed ID: 18776046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor.
    Wallisch M; Nelson CS; Mulvaney JM; Hernandez HS; Smith SA; Olsen GD
    Biochem Pharmacol; 2007 Jun; 73(11):1818-28. PubMed ID: 17343833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase C-mediated inhibition of transmembrane signalling through CCK(A) and CCK(B) receptors.
    Smeets RL; Fouraux MA; van Emst-de Vries SE; De Pont JJ; Willems PH
    Br J Pharmacol; 1998 Mar; 123(6):1189-97. PubMed ID: 9559904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular handling of unoccupied and agonist-stimulated cholecystokinin receptor determined by immunolocalization.
    Fischer de Toledo C; Roettger BF; Morys-Wortmann C; Schmidt WE; Miller LJ
    Am J Physiol; 1997 Mar; 272(3 Pt 1):G488-97. PubMed ID: 9124569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of agmatine on DAMGO-induced mu-opioid receptor down-regulation and internalization via activation of IRAS, a candidate for imidazoline I(1) receptor.
    Gao Y; Li F; Wu N; Su RB; Liu Y; Lu XQ; Liu Y; Li J
    Eur J Pharmacol; 2008 Dec; 599(1-3):18-23. PubMed ID: 18845140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay.
    Fichna J; Staniszewska R; Poels J; Vanden Broeck J; Janecka A
    Chem Biol Drug Des; 2007 Sep; 70(3):247-53. PubMed ID: 17718719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.
    Hadac EM; Ji Z; Pinon DI; Henne RM; Lybrand TP; Miller LJ
    J Med Chem; 1999 Jun; 42(12):2105-11. PubMed ID: 10377216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic domain of human Fcalpha/mu receptor is required for ligand internalization.
    Yang L; Shen L; Shao Y; Zhao Q; Zhang W
    Cell Immunol; 2009; 258(1):78-82. PubMed ID: 19393604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
    Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
    J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.